AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers rega ...

Amgen today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the risk of death by 40% and significantly extended median overall ...

Snorkel AI announced general availability of two new product offerings on the Snorkel AI Data Development Platform: Snorkel Evaluate and Snorkel Expert Data-as-a-Service. These launches advance its ...

After calling out big food brands for falsely claiming that their products were healthy, Himatsingka is ready for the next ...

There’s a profound difference between depriving yourself—believing certain foods are off-limits because they’re “bad”—and ...

Esther Rajavelu was appointed as Spero’s President and Chief Executive Officer, effective May 2, 2025. Ms. Rajavelu has also been nominated for election to the Board of Directors at Spero’s 2025 ...

Prayagraj: The Uttar Pradesh Public Service Commission(UPPSC) is revolutionising the recruitment process for assistant professors in 171 govt colleges across the state. Ditching the traditional ...

Mumbai: Mumbai is poised to open another leg of its first underground Metro, with Phase 2 of Metro Line 3 — the Aqua Line — set to become operational from Saturday, May 10. Chief Minister ...

In a big leap for Mumbai’s public transport, Metro Line 3's second phase—connecting Bandra-Kurla Complex (BKC) to Acharya Atre Chowk in Worli—officially began operations on Saturday ...

Dive into Sprunki MSI Canon Phase 3, where new characters and immersive soundscapes deepen the narrative. Experience a thrilling evolution of dark themes. Sprunki MSI Phase 3 represents a thrilling ...

These version 3.3 Phase 1 Banners start on Wednesday 21st May and are expected to end on Wednesday 11th June. These version 3.3 Phase 2 Banners are expected to run from Wednesday 11th June to ...

In 2024, Merck announced the initiation of the Phase 2/3 REJOICE-Ovarian01 trial evaluating raludotatug deruxtecan (R-DXd), an investigational potential first-in-class CDH6 directed DXd antibody ...